The Decision Resources Physician & Payer Forum Nociceptive Pain Webinar

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser

Inflammatory and Nociceptive Pain: Physician and Payer Insights Regarding the First-in-Class Biologic Analgesic, Tanezumab

— A Webinar from Decision Resources

Based on our Physician & Payer Forum report entitled Biologics and Formulations for Inflammatory and Nociceptive Pain: Will These Agents Gain Widespread Physician and Payer Acceptance Despite a Crowded Market?, Decision Resources is offering an exclusive webinar entitled Inflammatory and Nociceptive Pain: Physician and Payer Insights Regarding the First-in-Class Biologic Analgesic, Tanezumab. Because this webinar will feature major report findings, it is ONLY available to purchasers of this report.

Please contact us to learn how can purchase this Physician & Payer Forum report and attend the webinar.

Two-thirds of the total prescription analgesics market in the United States is comprised of drugs for inflammatory and nociceptive pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics are the mainstay treatment for conditions associated with inflammatory and nociceptive pain, but they are associated with significant cardiovascular and gastrointestinal side effects and the risk of drug abuse, respectively. Among the key emerging analgesics expected to launch in the next three years, Pfizer’s tanezumab has the greatest potential to significantly alter the treatment paradigm of inflammatory and nociceptive pain conditions. This presentation will focus on the survey responses of 50 pain specialists, 52 rheumatologists, 50 PCPs and 20 managed care organization pharmacy directors regarding their anticipated prescription and reimbursement of this potentially revolutionary first-in-class biologic.

This webinar, presented by Decision Resources’ analyst Natalie Taylor, Ph.D., will answer the following questions:

What proportion of physicians expect to prescribe tanezumab if it is launched? To what patient populations do pain specialists, rheumatologists and PCPs expect to prescribe tanezumab? Among physicians that would prescribe tanezumab, what are their patient share estimates for the drug? Given tanezumab’s unique clinical profile, do physicians anticipate they would prescribe tanezumab as a monotherapy or as an adjunct treatment to oral analgesics?
What do physicians perceive will be the biggest barrier to prescribing tanezumab to their patients? What subtypes of chronic low back pain and osteoarthritis sufferers do physicians believe will be most likely to benefit from tanezumab? For what line of therapy would tanezumab be used in patients and what analgesics would be tried first in the treatment algorithm, according to physicians? How will tanezumab’s delivery impact prescribing decision by physician type? What are the overall opinions of pain specialists, rheumatologists and PCPs of the efficacy, safety and delivery profile of tanezumab, and how do they compare?
Will cost be a deciding factor for pain specialists, rheumatologists and PCPs when they prescribe tanezumab? At what price point will cost prevent physicians from prescribing tanezumab? What are the most influential characteristics determining tier placement of analgesics according to pharmacy directors? How many treatment steps will managed care organizations require before reimbursing tanezumab?

Dr. Taylor will conduct a live Q & A session after the presentation.

Registration

Inflammatory and Nociceptive Pain: Physician and Payer Insights Regarding the First-in-Class Biologic Analgesic, Tanezumab

June 16, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Physician & Payer Forum report and attend the webinar, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Webinar Details

Date & Time
Wednesday, June 16, 2010
10 a.m. ET, 4 p.m. CET

Presentation: 30 minutes

Q & A: 10 minutes

About the Speaker

Natalie C. Taylor, Ph.D., is a research analyst on the Cognos team at Decision Resources where she specializes in psychiatric disorders and pain. Before joining the company, Dr. Taylor received her Ph.D. in molecular, cellular and systems physiology from Dartmouth College. There, she researched the modulation of breathing by brain stem serotonergic neurons under the mentorship of Dr. Eugene Nattie, M.D. Prior to her graduate studies, she worked as a research assistant intern in the research laboratories of Merck & Co., where she took part in the development of novel compounds to treat neuropathic pain. She obtained her B.S. in biology from Dickinson College in Carlisle, Pennsylvania.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.